Athenex, Inc (ATNX)

Etorro trading 970x250
Athenex, Inc (ATNX) Logo

About Athenex, Inc

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. Address: Conventus Building, Buffalo, NY, United States, 14203

Athenex, Inc News and around…

Latest news about Athenex, Inc (ATNX) common stock and company :

Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
18 Oct, 2021 Yahoo! Finance

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent protection helps validate the groundbreaking innovation of Dr. Leonid Metelitsa in harnessing NKT cell technologies for adoptive cell transfer therapy in oncology BUFFALO, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), the leading developer of NKT cell therapy and the Center for Cell and Ge

Interesting ATNX Put And Call Options For December 17th
15 Oct, 2021 FinancialContent

Investors in Athenex Inc (ATNX) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATNX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Thursday 10/14 Insider Buying Report: SLGG, ATNX
14 Oct, 2021 FinancialContent

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

3 Penny Stocks Insiders Are Buying
14 Oct, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)
12 Oct, 2021 Yahoo! Finance

Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
11 Oct, 2021 Yahoo! Finance

BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oral paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast cancer (mBC). The purpose of the meetin

Sum Up The Pieces: VTWV Could Be Worth $168
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $167.98 per unit.

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
27 Sep, 2021 FinancialContent

Gainers Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market ...

Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis
27 Sep, 2021 FinancialContent
5 Penny Stocks To Buy According To Insiders In September
16 Sep, 2021 FinancialContent
Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial
16 Sep, 2021 FinancialContent

Athenex Inc(NASDAQ: ATNX)announced data presentationfrom a Phase 1 study evaluating encequidar (Oral Paclitaxel) in ...

53 Biggest Movers From Yesterday
16 Sep, 2021 FinancialContent

Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO ...

Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
16 Sep, 2021 FinancialContent

Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies

38 Stocks Moving In Wednesday's Mid-Day Session
15 Sep, 2021 FinancialContent

Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States ...

Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit
15 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
15 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're jumping back into the stock market as we take a look at the biggest pre-market stock movers for Wednesday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

26 Stocks Moving in Wednesday's Pre-Market Session
15 Sep, 2021 FinancialContent

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) rose 46.1% to $0.6699 in pre-market trading after dropping 11% on Tuesday. MeaTech 3D Ltd. ...

Here's Why Ziopharm Oncology Stock Is Up 18% This Week
10 Sep, 2021 FinancialContent

Recent insider stock purchases were more than a little encouraging.

Analysts Expect IBBQ Will Reach $32
07 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $32.44 per unit.

Why Shares of Ziopharm Oncology Jumped on Wednesday
01 Sep, 2021 FinancialContent

The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript
06 Aug, 2021 FinancialContent

ATNX earnings call for the period ending June 30, 2021.

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
05 Aug, 2021 FinancialContent

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest ...

Athenex, Inc (ATNX) is a NASDAQ Common Stock listed in , ,

970x250